US5589489A
(en)
*
|
1993-12-15 |
1996-12-31 |
Zeneca Limited |
Cyclic amide derivatives for treating asthma
|
US5434158A
(en)
*
|
1994-04-26 |
1995-07-18 |
Merck & Co., Inc. |
Spiro-substituted azacycles as neurokinin-3 antagonists
|
GB9408872D0
(en)
*
|
1994-05-03 |
1994-06-22 |
Zeneca Ltd |
Heterocyclic compounds
|
GB9415996D0
(en)
*
|
1994-08-08 |
1994-09-28 |
Merck Sharp & Dohme |
Therapeutic agents
|
TW432061B
(en)
*
|
1994-08-09 |
2001-05-01 |
Pfizer Res & Dev |
Lactams
|
US5998444A
(en)
*
|
1995-10-24 |
1999-12-07 |
Zeneca Ltd. |
Piperidinyl compounds as NK1 or NK2 antagonists
|
EP0709375B1
(en)
*
|
1994-10-25 |
2005-05-18 |
AstraZeneca AB |
Therapeutic heterocycles
|
US6008223A
(en)
*
|
1994-10-27 |
1999-12-28 |
Zeneca Limited |
Therapeutic compounds
|
GB9502644D0
(en)
*
|
1995-02-10 |
1995-03-29 |
Zeneca Ltd |
Heterocyclic derivatives
|
WO1996033189A1
(en)
*
|
1995-04-19 |
1996-10-24 |
Merck & Co., Inc. |
Process for the preparation of spiroindolines
|
GB9508786D0
(en)
|
1995-04-29 |
1995-06-21 |
Zeneca Ltd |
Substituted heterocycles
|
US5795894A
(en)
*
|
1995-05-02 |
1998-08-18 |
Schering Corporation |
Piperazino derivatives as neurokinn antagonists
|
US5719156A
(en)
*
|
1995-05-02 |
1998-02-17 |
Schering Corporation |
Piperazino derivatives as neurokinin antagonists
|
US5696267A
(en)
*
|
1995-05-02 |
1997-12-09 |
Schering Corporation |
Substituted oximes, hydrazones and olefins as neurokinin antagonists
|
US5654316A
(en)
*
|
1995-06-06 |
1997-08-05 |
Schering Corporation |
Piperidine derivatives as neurokinin antagonists
|
US5892039A
(en)
*
|
1995-08-31 |
1999-04-06 |
Schering Corporation |
Piperazino derivatives as neurokinin antagonists
|
US5723616A
(en)
*
|
1995-10-27 |
1998-03-03 |
Merck & Co., Inc. |
Process for the preparation of a growth hormone secretagogue
|
US6028196A
(en)
*
|
1995-10-27 |
2000-02-22 |
Merck & Co., Inc. |
Process for the preparation of a growth hormone secretagogue
|
GB9523526D0
(en)
*
|
1995-11-17 |
1996-01-17 |
Zeneca Ltd |
Therapeutic compounds
|
JP2000500760A
(ja)
*
|
1995-11-23 |
2000-01-25 |
メルク シヤープ エンド ドーム リミテツド |
スピロピペリジン誘導体およびタキキニン拮抗薬としてのその使用
|
RU2135494C1
(ru)
*
|
1995-12-01 |
1999-08-27 |
Санкио Компани Лимитед |
Гетероциклические соединения и композиция на их основе, проявляющая антагонистическое действие в отношении рецепторов тахикинина
|
GB9601724D0
(en)
*
|
1996-01-29 |
1996-03-27 |
Merck Sharp & Dohme |
Therapeutic agents
|
GB9603137D0
(en)
*
|
1996-02-15 |
1996-04-17 |
Merck Sharp & Dohme |
Therapeutic agents
|
GB9603136D0
(en)
*
|
1996-02-15 |
1996-04-17 |
Merck Sharp & Dohme |
Therapeutic agents
|
US5869488A
(en)
*
|
1996-05-01 |
1999-02-09 |
Schering Corporation |
Piperazino derivatives as neurokinin antagonists
|
US5691362A
(en)
*
|
1996-06-05 |
1997-11-25 |
Schering-Plough Corporation |
Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists
|
PL330235A1
(en)
*
|
1996-06-21 |
1999-05-10 |
Merck Sharp & Dohme |
Derivatives of spiropiperidine and their application as therapeutic agents
|
US6046333A
(en)
*
|
1996-10-25 |
2000-04-04 |
Merck & Co., Inc. |
Convergent process for the preparation of a growth hormone secretagogue
|
US5789422A
(en)
*
|
1996-10-28 |
1998-08-04 |
Schering Corporation |
Substituted arylalkylamines as neurokinin antagonists
|
IL129430A0
(en)
*
|
1996-10-28 |
2000-02-17 |
Schering Corp |
Substituted arylalkylamines as neurokinin antagonists
|
US5945428A
(en)
*
|
1996-11-01 |
1999-08-31 |
Schering Corporation |
Substituted oximes, hydrazones and olefins as neurokinin antagonists
|
US5962462A
(en)
*
|
1996-12-13 |
1999-10-05 |
Merck & Co., Inc. |
Spiro-substituted azacycles as modulators of chemokine receptor activity
|
US5783579A
(en)
*
|
1996-12-20 |
1998-07-21 |
Schering Corporation |
Spiro-substituted azacyclic-substituted piperazino derivatives as neurokinin antagonists
|
TR199902943T2
(xx)
|
1997-05-30 |
2000-05-22 |
Sankyo Company Limited |
Optik bak�mdan aktif s�lfoksit t�revinin tuzlar�.
|
US6013644A
(en)
*
|
1997-12-12 |
2000-01-11 |
Merck & Co., Inc. |
Spiro-substituted azacycles as modulators of chemokine receptor activity
|
US6063926A
(en)
*
|
1998-11-18 |
2000-05-16 |
Schering Corporation |
Substituted oximes as neurokinin antagonists
|
GB9907571D0
(en)
|
1999-04-06 |
1999-05-26 |
Zeneca Ltd |
Compounds
|
WO2002089802A2
(en)
|
2001-05-08 |
2002-11-14 |
Schering Corporation |
Use of neurokinin receptor antagonists to treat androgen-dependent diseases
|
SI1423381T1
(sl)
|
2001-09-06 |
2007-04-30 |
Schering Corp Patent Dept K 6 |
Inhibitorji 17-beta-hidroksisteroidne dehidrogenaze tipa 3 za zdravljenje androgensko odvisnih bolezni
|
CA2463626C
(en)
|
2001-10-17 |
2011-05-24 |
Schering Corporation |
Piperidine- and piperazineacetamines as 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
|
GB0213715D0
(en)
|
2002-06-14 |
2002-07-24 |
Syngenta Ltd |
Chemical compounds
|
EP1558250A4
(en)
*
|
2002-10-30 |
2006-11-02 |
Merck & Co Inc |
GAMMA AMINOAMIDE MODULATORS OF THE CHEMOKIN RECEPTOR ACTIVITY
|
TW200524868A
(en)
*
|
2003-07-31 |
2005-08-01 |
Zeria Pharm Co Ltd |
Benzylamine derivatives
|
US7091211B2
(en)
|
2003-07-31 |
2006-08-15 |
Merck & Co., Inc. |
Cyclopentyl modulators of chemokine receptor activity
|
GB0328908D0
(en)
|
2003-12-12 |
2004-01-14 |
Syngenta Participations Ag |
Chemical compounds
|
GB0328907D0
(en)
|
2003-12-12 |
2004-01-14 |
Syngenta Participations Ag |
Chemical compounds
|
US7381738B2
(en)
|
2004-02-19 |
2008-06-03 |
Bristol-Myers Squibb Company |
Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
|
US7479496B2
(en)
|
2004-02-19 |
2009-01-20 |
Bristol-Myers Squibb Company |
Substituted spiro azabicyclics as modulators of chemokine receptor activity
|
US7230022B2
(en)
|
2004-02-19 |
2007-06-12 |
Bristol-Myers Squibb Company |
Substituted fused bicyclic amines as modulators of chemokine receptor activity
|
US7288563B2
(en)
|
2004-02-19 |
2007-10-30 |
Bristol-Myers Squibb Company |
Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
|
BRPI0509307A
(pt)
|
2004-03-29 |
2007-09-04 |
Pfizer |
compostos de alfa aril ou heteroaril metil beta piperidino propanamida como antagonistas do receptor orl1
|
KR101389246B1
(ko)
|
2004-07-15 |
2014-04-24 |
브리스톨-마이어스스퀴브컴파니 |
아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및 이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
|
US8604200B2
(en)
|
2005-03-08 |
2013-12-10 |
Janssen Pharmaceutica N.V. |
Diaza-spiro-{4,4}-nonane derivatives as neurokinin (NK1) antagonists
|
US8362075B2
(en)
|
2005-05-17 |
2013-01-29 |
Merck Sharp & Dohme Corp. |
Cyclohexyl sulphones for treatment of cancer
|
KR101594898B1
(ko)
|
2005-07-15 |
2016-02-18 |
알바니 몰레큘라 리써치, 인크. |
아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
|
JP4879988B2
(ja)
|
2005-09-29 |
2012-02-22 |
メルク・シャープ・エンド・ドーム・コーポレイション |
メラノコルチン−4受容体モジュレーターとしてのアシル化スピロピペリジン誘導体
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
EP2946778A1
(en)
|
2006-09-22 |
2015-11-25 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
GEP20115337B
(en)
|
2007-01-10 |
2011-11-25 |
St Di Ricerche Di Biologia Molecolare P Angeletti Spa |
Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
|
JP5319518B2
(ja)
|
2007-04-02 |
2013-10-16 |
Msd株式会社 |
インドールジオン誘導体
|
US8389553B2
(en)
|
2007-06-27 |
2013-03-05 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
EP2247185B1
(en)
|
2008-03-03 |
2014-04-16 |
Tiger Pharmatech |
Tyrosine kinase inhibitors
|
GB0808030D0
(en)
|
2008-05-01 |
2008-06-11 |
Glaxo Wellcome Mfg Pte Ltd |
Novel compounds
|
US9156812B2
(en)
|
2008-06-04 |
2015-10-13 |
Bristol-Myers Squibb Company |
Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
|
UA105182C2
(ru)
|
2008-07-03 |
2014-04-25 |
Ньюрексон, Інк. |
Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
|
EP2318388A2
(en)
|
2008-07-23 |
2011-05-11 |
Schering Corporation |
Tricyclic spirocycle derivatives and methods of use thereof
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
WO2010132437A1
(en)
|
2009-05-12 |
2010-11-18 |
Albany Molecular Research, Inc. |
Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
|
JP5739415B2
(ja)
|
2009-05-12 |
2015-06-24 |
ブリストル−マイヤーズ スクウィブ カンパニー |
(S)−7−([1,2,4]トリアゾロ[1,5−a]ピリジン−6−イル)−4−(3,4−ジクロロフェニル)−1,2,3,4−テトラヒドロイソキノリンの結晶形態およびその使用
|
EA020553B1
(ru)
|
2009-05-12 |
2014-12-30 |
Олбани Молекьюлар Рисерч, Инк. |
7-([1,2,4]ТРИАЗОЛО[1,5-α]ПИРИДИН-6-ИЛ)-4-(3,4-ДИХЛОРФЕНИЛ)-1,2,3,4-ТЕТРАГИДРОИЗОХИНОЛИН, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ И ПСИХИЧЕСКИХ РАССТРОЙСТВ
|
MX2012004377A
(es)
|
2009-10-14 |
2012-06-01 |
Merck Sharp & Dohme |
Piperidinas sustituidas que aumentan la actividad de p53 y sus usos.
|
AU2011212478B2
(en)
|
2010-02-05 |
2014-11-06 |
Intervet International B.V. |
Spiroindoline Compounds For Use as Anthelminthics
|
EP2584903B1
(en)
|
2010-06-24 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
EP2601293B1
(en)
|
2010-08-02 |
2017-12-06 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
AU2011292261B2
(en)
|
2010-08-17 |
2015-05-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
|
EP2608669B1
(en)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
EP2613782B1
(en)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
EP2615916B1
(en)
|
2010-09-16 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel erk inhibitors
|
EP3327125B1
(en)
|
2010-10-29 |
2020-08-05 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
|
WO2012087772A1
(en)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
US20140045832A1
(en)
|
2011-04-21 |
2014-02-13 |
Piramal Enterprises Limited |
Insulin-Like Growth Factor-1 Receptor Inhibitors
|
EP2739626B1
(en)
|
2011-08-04 |
2016-05-04 |
Intervet International B.V. |
Novel spiroindoline compounds
|
WO2013063214A1
(en)
|
2011-10-27 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
EP3453762B1
(en)
|
2012-05-02 |
2021-04-21 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
US9855286B2
(en)
|
2012-05-18 |
2018-01-02 |
Gruenenthal Gmbh |
Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
|
US20130310385A1
(en)
|
2012-05-18 |
2013-11-21 |
Gruenenthal Gmbh |
Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
|
US9320729B2
(en)
|
2012-05-18 |
2016-04-26 |
Gruenenthal Gmbh |
Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
|
US20130310435A1
(en)
|
2012-05-18 |
2013-11-21 |
Gruenenthal Gmbh |
Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
|
MX2015004041A
(es)
|
2012-09-28 |
2015-07-06 |
Merck Sharp & Dohme |
Compuestos novedosos que son inhibidores de erk.
|
RU2660349C2
(ru)
|
2012-11-28 |
2018-07-05 |
Мерк Шарп И Доум Корп. |
Композиции и способы для лечения злокачественной опухоли
|
US8846657B2
(en)
|
2012-12-20 |
2014-09-30 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as HDM2 inhibitors
|
EP2951180B1
(en)
|
2013-01-30 |
2018-05-02 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
EP2881391A1
(en)
|
2013-12-05 |
2015-06-10 |
Bayer Pharma Aktiengesellschaft |
Spiroindoline carbocycle derivatives and pharmaceutical compositions thereof
|
CA2967097A1
(en)
|
2014-11-21 |
2016-05-26 |
Laboratorios Del Dr. Esteve, S.A. |
Spiro-isoquinoline-1,4'-piperidine compounds having multimodal activity against pain
|
EP3706742B1
(en)
|
2017-11-08 |
2023-03-15 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
WO2020033284A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
US11993602B2
(en)
|
2018-08-07 |
2024-05-28 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|